Browse MED16

Summary
SymbolMED16
Namemediator complex subunit 16
Aliases DRIP92; TRAP95; THRAP5; thyroid hormone receptor associated protein 5; thyroid hormone receptor-associated p ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus
Domain PF11635 Mediator complex subunit 16
Function

Component of the Mediator complex, a coactivator involved in the regulated transcription of nearly all RNA polymerase II-dependent genes. Mediator functions as a bridge to convey information from gene-specific regulatory proteins to the basal RNA polymerase II transcription machinery. Mediator is recruited to promoters by direct interactions with regulatory proteins and serves as a scaffold for the assembly of a functional preinitiation complex with RNA polymerase II and the general transcription factors.

> Gene Ontology
 
Biological Process GO:0006352 DNA-templated transcription, initiation
GO:0006367 transcription initiation from RNA polymerase II promoter
GO:0009755 hormone-mediated signaling pathway
GO:0010469 regulation of receptor activity
GO:0030518 intracellular steroid hormone receptor signaling pathway
GO:0030521 androgen receptor signaling pathway
GO:0030522 intracellular receptor signaling pathway
GO:0043401 steroid hormone mediated signaling pathway
GO:0048545 response to steroid hormone
GO:0071383 cellular response to steroid hormone stimulus
GO:0071396 cellular response to lipid
GO:0071407 cellular response to organic cyclic compound
GO:2000273 positive regulation of receptor activity
Molecular Function GO:0003713 transcription coactivator activity
GO:0008134 transcription factor binding
GO:0010861 thyroid hormone receptor activator activity
GO:0030374 ligand-dependent nuclear receptor transcription coactivator activity
GO:0030375 thyroid hormone receptor coactivator activity
GO:0030545 receptor regulator activity
GO:0030546 receptor activator activity
GO:0035257 nuclear hormone receptor binding
GO:0042809 vitamin D receptor binding
GO:0046966 thyroid hormone receptor binding
GO:0051427 hormone receptor binding
Cellular Component GO:0016592 mediator complex
> KEGG and Reactome Pathway
 
KEGG hsa04919 Thyroid hormone signaling pathway
Reactome R-HSA-1266738: Developmental Biology
R-HSA-535734: Fatty acid, triacylglycerol, and ketone body metabolism
R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-1430728: Metabolism
R-HSA-556833: Metabolism of lipids and lipoproteins
R-HSA-1989781: PPARA activates gene expression
R-HSA-400206: Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
R-HSA-381340: Transcriptional regulation of white adipocyte differentiation
Summary
SymbolMED16
Namemediator complex subunit 16
Aliases DRIP92; TRAP95; THRAP5; thyroid hormone receptor associated protein 5; thyroid hormone receptor-associated p ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between MED16 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolMED16
Namemediator complex subunit 16
Aliases DRIP92; TRAP95; THRAP5; thyroid hormone receptor associated protein 5; thyroid hormone receptor-associated p ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of MED16 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.56 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolMED16
Namemediator complex subunit 16
Aliases DRIP92; TRAP95; THRAP5; thyroid hormone receptor associated protein 5; thyroid hormone receptor-associated p ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of MED16 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0870.786
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.3010.876
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.3750.779
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.2320.459
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.4060.864
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.010.997
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1540.633
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.0580.96
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1830.895
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.2620.85
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.110.956
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1180.0669
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of MED16 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 1417011.8-11.80.488
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103033.3-33.30.231
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91633.337.5-4.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 596044.415.61
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47028.6-28.60.491
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11139.109.10.458
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 6116.7016.71
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolMED16
Namemediator complex subunit 16
Aliases DRIP92; TRAP95; THRAP5; thyroid hormone receptor associated protein 5; thyroid hormone receptor-associated p ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MED16. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolMED16
Namemediator complex subunit 16
Aliases DRIP92; TRAP95; THRAP5; thyroid hormone receptor associated protein 5; thyroid hormone receptor-associated p ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MED16. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MED16.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolMED16
Namemediator complex subunit 16
Aliases DRIP92; TRAP95; THRAP5; thyroid hormone receptor associated protein 5; thyroid hormone receptor-associated p ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MED16. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolMED16
Namemediator complex subunit 16
Aliases DRIP92; TRAP95; THRAP5; thyroid hormone receptor associated protein 5; thyroid hormone receptor-associated p ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of MED16 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolMED16
Namemediator complex subunit 16
Aliases DRIP92; TRAP95; THRAP5; thyroid hormone receptor associated protein 5; thyroid hormone receptor-associated p ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between MED16 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolMED16
Namemediator complex subunit 16
Aliases DRIP92; TRAP95; THRAP5; thyroid hormone receptor associated protein 5; thyroid hormone receptor-associated p ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting MED16 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.